SPHK1 and breast carcinoma: In this study, we examine the prognostic significance of SPHK1 in breast cancer and address the therapeutic potential of targeting SPHK1 in TNBCs, using SPHK1 knockdown experiments or treatment with a pharmacological SPHK1 inhibitor, 2,2-dimethyl-4S-(1-oxo-2-hexadecyn-1-yl)-1,1-dimethylethyl ester-3-oxazolidinecarboxylic acid (SKI-5C).